Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer" and the "Commentary by Antonio Ieni and Giovanni Tuccari"

Overview

Journal J Breast Cancer

Date 2016 Oct 11

PMID 27721886

Authors

Christine A Fargeas

Denis Corbeil

Affiliations

Soon will be listed here.

References

Fargeas C, Huttner W, Corbeil D . Nomenclature of prominin-1 (CD133) splice variants - an update. Tissue Antigens. 2007; 69(6):602-6. DOI: 10.1111/j.1399-0039.2007.00825.x. View

Latorre E, Carelli S, Raimondi I, DAgostino V, Castiglioni I, Zucal C . The Ribonucleic Complex HuR-MALAT1 Represses CD133 Expression and Suppresses Epithelial-Mesenchymal Transition in Breast Cancer. Cancer Res. 2016; 76(9):2626-36. DOI: 10.1158/0008-5472.CAN-15-2018. View

Karbanova J, Laco J, Marzesco A, Janich P, Vobornikova M, Mokry J . Human prominin-1 (CD133) is detected in both neoplastic and non-neoplastic salivary gland diseases and released into saliva in a ubiquitinated form. PLoS One. 2014; 9(6):e98927. PMC: 4050055. DOI: 10.1371/journal.pone.0098927. View

Prat A, Perou C . Mammary development meets cancer genomics. Nat Med. 2009; 15(8):842-4. DOI: 10.1038/nm0809-842. View

Kapucuoglu N, Bozkurt K, Baspinar S, Kocer M, Eroglu H, Akdeniz R . The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol Res Pract. 2015; 211(10):740-7. DOI: 10.1016/j.prp.2015.05.011. View

Karbanova J, Missol-Kolka E, Fonseca A, Lorra C, Janich P, Hollerova H . The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem. 2008; 56(11):977-93. PMC: 2569896. DOI: 10.1369/jhc.2008.951897. View

Florek M, Haase M, Marzesco A, Freund D, Ehninger G, Huttner W . Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 2004; 319(1):15-26. DOI: 10.1007/s00441-004-1018-z. View

Han Z, Chen Z, Zheng R, Cheng Z, Gong X, Wang D . Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis. World J Surg Oncol. 2015; 13:56. PMC: 4344776. DOI: 10.1186/s12957-015-0486-9. View

Corbeil D, Fargeas C, Jaszai J . CD133 might be a pan marker of epithelial cells with dedifferentiation capacity. Proc Natl Acad Sci U S A. 2014; 111(15):E1451-2. PMC: 3992674. DOI: 10.1073/pnas.1400195111. View

10.

Corbeil D, Karbanova J, Fargeas C, Jaszai J . Prominin-1 (CD133): Molecular and Cellular Features Across Species. Adv Exp Med Biol. 2012; 777:3-24. DOI: 10.1007/978-1-4614-5894-4_1. View

11.

Bock C, Kuhn C, Ditsch N, Krebold R, Heublein S, Mayr D . Strong correlation between N-cadherin and CD133 in breast cancer: role of both markers in metastatic events. J Cancer Res Clin Oncol. 2014; 140(11):1873-81. DOI: 10.1007/s00432-014-1750-z. View

12.

Anderson L, Boulanger C, Smith G, Carmeliet P, Watson C . Stem cell marker prominin-1 regulates branching morphogenesis, but not regenerative capacity, in the mammary gland. Dev Dyn. 2011; 240(3):674-81. PMC: 3094854. DOI: 10.1002/dvdy.22539. View

13.

Mansour S, Atwa M . Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma. Asian Pac J Cancer Prev. 2015; 16(17):7491-6. DOI: 10.7314/apjcp.2015.16.17.7491. View

14.

Marzesco A . Prominin-1-containing membrane vesicles: origins, formation, and utility. Adv Exp Med Biol. 2012; 777:41-54. DOI: 10.1007/978-1-4614-5894-4_3. View

15.

Aomatsu N, Yashiro M, Kashiwagi S, Takashima T, Ishikawa T, Ohsawa M . CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One. 2012; 7(9):e45865. PMC: 3457956. DOI: 10.1371/journal.pone.0045865. View

16.

Immervoll H, Hoem D, Sakariassen P, Steffensen O, Molven A . Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 2008; 8:48. PMC: 2268945. DOI: 10.1186/1471-2407-8-48. View

17.

Kim S, Kim Y, Jang E, Seo K, Kim J . Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer. J Breast Cancer. 2016; 18(4):347-55. PMC: 4705086. DOI: 10.4048/jbc.2015.18.4.347. View

18.

Ieni A, Tuccari G . Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer". J Breast Cancer. 2016; 19(1):96-8. PMC: 4822115. DOI: 10.4048/jbc.2016.19.1.96. View

19.

OBrien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel A . Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer. 2013; 49(8):1845-59. DOI: 10.1016/j.ejca.2013.01.017. View

20.

Hermansen S, Christensen K, Jensen S, Kristensen B . Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem. 2011; 59(4):391-407. PMC: 3201141. DOI: 10.1369/0022155411400867. View